Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Psoriasis Market Size, Value And Growth Trends Through 2030
The psoriasis market has experienced notable expansion over the past few years. Its value is projected to rise from $28.93 billion in 2025 to $31.41 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.5%. This historical growth has been driven by factors such as the rising incidence of autoimmune skin conditions, extensive use of corticosteroids, enhanced diagnostic capabilities in dermatology, the proliferation of hospital-based dermatology departments, and increased public understanding of chronic skin disorders.
The market for psoriasis treatments is anticipated to experience significant expansion in the coming years, reaching a valuation of $44.79 billion by 2030 with a compound annual growth rate (CAGR) of 9.3%. This projected growth during the forecast period is driven by factors such as the increasing approval of biologic drugs, heightened awareness among patients, more frequent diagnoses of severe psoriasis, the proliferation of specialized clinics, and elevated healthcare expenditures dedicated to dermatology. Key trends shaping this period include a growing preference for biologic therapies to manage the condition, a shift toward longer-term disease management strategies, escalating demand for injectable treatment options, the broadening of hospital-based and specialty dermatology services, and an intensified emphasis on addressing moderate-to-severe cases of psoriasis.
Download A Free Sample Report For Comprehensive Market Insights:
Psoriasis Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing number of individuals diagnosed with psoriasis is anticipated to boost the expansion of the psoriasis market moving forward. Psoriasis represents a persistent autoimmune skin condition where abnormally rapid skin cell accumulation results in inflammation, flaking, and physical distress, frequently necessitating ongoing medical care and oversight. This rise in psoriasis cases stems from an overactive immune mechanism that erroneously targets healthy skin cells, a process frequently initiated or worsened by environmental influences like infections, psychological strain, or cutaneous damage. The growing frequency of psoriasis fuels demand for biologics, topical medications, immunomodulators, and phototherapy treatments intended to minimize exacerbations, alleviate symptoms, and elevate patient well-being. For example, in 2025, based on data from the Global Psoriasis Atlas—a UK-based research entity specializing in psoriasis—approximately 43 million people have psoriasis as identified through physician or dermatologist assessments, whereas about 102 million individuals report having the condition via self-diagnosed cases. Consequently, the escalating occurrence of psoriasis patients is propelling the advancement of the psoriasis market.
Psoriasis Market Segment Breakdown: Which Categories Generate The Most Revenue?
The psoriasis market covered in this report is segmented –
1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor
2) By Drug Types: Small molecules, Biologics
3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis
4) By Route Of Administration: Oral, Topical, Injectable
5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce
Subsegments:
1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)
2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)
3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)
Psoriasis Market Trends Reshaping Industry Growth
Key players in the psoriasis market are prioritizing product innovation and formulation improvements, including autoinjector delivery systems for biosimilars, to boost patient adherence, convenience, and treatment results while preserving the effectiveness and safety profiles of reference biologics. These systems allow for self-administration, lessen injection discomfort, and encourage wider acceptance of biosimilar therapies throughout Europe and other regions. For example, in May 2025, Sandoz, a biopharmaceutical firm based in Switzerland, introduced the Pyzchiva autoinjector, the first commercially accessible autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is engineered to offer straightforward, precise, and patient-friendly administration of biosimilar ustekinumab, fostering better adherence in the management of chronic psoriasis. This introduction underscores a market shift toward improving patient-focused delivery options for biologics and biosimilars, thereby enhancing accessibility and convenience for those affected by psoriasis.
Psoriasis Market Key Players And Strategic Industry Positioning
Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy
Access The Complete Psoriasis Market Report:
Psoriasis Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model